Wirtschaftliche, arbeitsrechtliche und sozialpolitische Konsequenzen und Optionen des gemeinsamen europäischen Binnenmarktes: Europa 1993 ein European der Unternehmer? In diesem Reader wird der Frage nachgegangen, ob und in welchem Ausmaße die zu erwartenden gesamtwirtschaftlichen...

Dieser Beitrag untersucht die quantitativen Efgekte der jüngst vom ECOFIN-Rat beschlossenen Übergangsregelung für die umsatzsteuerliche Behandlung des Handels in der EG nach 1992. Zunächst werden die Funktionsweise des bisherigen Bestimmungslandprinzips und der neuen Regelung beschrieben und...

Dokumentation des aktuellen Stands der Forschung zur Markenarchitekturbildung in der pharmazeutischen Industrie.

This study analyses 1400 research projects of the top 20 R&D-spending pharmaceuticals to identify the determinants of successful research projects. We provide clear evidence that externally sourced projects and projects involving biotechnologies perform better than internal projects and chemical...

Cross-border and domestic merger and acquisitions are considered as fastest means of growth and survival too. This study provides evidence on the value creation by applying inorganic growth strategies based on a sample of Indian pharmaceutical companies. Relying on the key financial ratios,...

Biotech revolution changed the pharmaceutical industry, triggering a wave of risky collaborations between rivals. Based on the research findings, we answer the question why cooperation in the field of immuno-oncology is a better strategy for Pfizer and Merck KGaA, which aim to achieve...

Purpose – The purpose of this paper is to examine the rationale and synergies of a Japanese firm's acquisition of India's leading pharmaceutical firm, Ranbaxy, and to answer the following pertinent questions: could Ranbaxy have been able to survive and succeed, had the firm not gone for this...

While the roles of the pharmaceutical industry remain pivotal to human welfare and longevity, the industry is characterized by huge Research and Development (R&D) cost of new drugs and enormous uncertainties on whether or not the drugs make it into the market. Corollary, originator companies...